Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Open access · bronzeAbstract readRandomized Controlled TrialClinical Trial, Phase III
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.JAMA network open · 2023Trial
- Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.Nature reviews. Clinical oncology · 2026Review
- From Payload-First Toward Dual-Mechanism Antibody-Drug Conjugates.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Cannabinoid CBOncogene · 2026Article
- Cardiotoxicity of monoclonal antibody-based therapies in breast cancer: a contemporary narrative review.Cardio-oncology (London, England) · 2026Review
- Targeted Therapies for Each Subtype of Breast Cancer.MedComm · 2026Review
- Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers.Molecular therapy. Oncology · 2026Review
- Review
- Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.Cancer discovery · 2026Article
- Anti-PD-1/PD-L1 Immunotherapy as a Potential Treatment Option for Lung Cancer: A Perspective Analysis of Opportunities and Challenges.Health science reports · 2026Article
- A real-world study on treatment after TKI progression in HER2-positive MBC.Therapeutic advances in medical oncology · 2026Article
- Review
- HER2-Low Breast Cancer at the Interface of Pathology and Technology: Toward Precision Management.Biomedicines · 2025Review
- Impacts of Antibody Structure and Mixtures on Receptor Signaling for Antibody-Dependent Cellular Cytotoxicity.The AAPS journal · 2025Article
- Improving survival outcomes of people with ABC: a global expert review and call-to-action for 2025-2035 (Goal 1).Breast (Edinburgh, Scotland) · 2025Review
- Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality.mAbs · 2025Article
- A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Decoding breast cancer: insights into molecular pathways & therapeutic approaches.Discover oncology · 2025Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 20 institutions in 12 countries.
Hope S RugoUniversity of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.ORCID 0000-0001-6710-4814
Seock-Ah ImCancer Research Institute, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea.ORCID 0000-0002-5396-6533
Fatima CardosoBreast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.ORCID 0000-0002-6692-2249
Javier CortesQuironsalud Group, International Breast Cancer Center (IBCC), Madrid and Barcelona, Spain.ORCID 0000-0001-7623-1583
Giuseppe CuriglianoIstituto Europeo di Oncologia, IRCCS, University of Milano, Milan, Italy.
Antonino MusolinoDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Mark D PegramStanford Comprehensive Cancer Institute, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0002-9743-8118
Thomas BachelotMedical Oncology Department, Centre Leon Berard, Lyon, France.ORCID 0000-0002-0866-9484
Gail S WrightFlorida Cancer Specialists & Research Institute, New Port Richey, FL.
Cristina SauraMedical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0001-8296-5065
Santiago Escrivá-de-RomaníMedical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Michelino De LaurentiisDepartment of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS "Fondazione Pascale," Naples, Italy.ORCID 0000-0001-9009-1572
Gary N SchwartzDivision of Medical Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH.ORCID 0000-0003-2537-9531
Timothy J PluardSaint Luke's Cancer Institute, Kansas City, MO.
Francesco RicciInstitut Curie, Paris, France.
William R GwinDivision of Medical Oncology/Seattle Cancer Care Alliance, University of Washington, Seattle, WA.
Christelle LevyCentre François Baclesse, Institut Normand du Sein, Caen, France.
Ursa Brown-GlabermanDivision of Hematology/Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM.
Jean-Marc FerreroDepartment of Medical Oncology, Centre Antoine Lacassagne, University Côte d'Azur, Nice, France.
Maaike de BoerDivision of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, GROW-School of Oncology and Developmental Biology, Maastricht, the Netherlands.
Sung-Bae KimAsan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID 0000-0001-5588-8332
Katarína PetrákováDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Denise A YardleySarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN.
Orit FreedmanRS McLaughlin Durham Regional Cancer Centre, Lakeridge Health, Oshawa, ON, Canada.
Erik H JakobsenDepartment of Oncology, Vejle Hospital, Vejle, Denmark.
Einav Nili Gal-YamChaim Sheba Medical Center, Breast Oncology Institute, Ramat Gan, Israel.
Rinat YerushalmiDavidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
Peter A FaschingDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.ORCID 0000-0003-4885-8471
Peter A KaufmanBreast Oncology, Division of Hematology/Oncology, University of Vermont Cancer Center, Burlington, VT.ORCID 0000-0003-3677-6807
Emily J AshleyMacroGenics, Inc, Rockville, MD.
Raul Perez-OlleMacroGenics, Inc, Rockville, MD.ORCID 0000-0001-9313-3694
Shengyan HongMacroGenics, Inc, Rockville, MD.
Minori Koshiji RosalesMacroGenics, Inc, Rockville, MD.
William J GradisharDivision of Hematology/Oncology, Northwestern University, Chicago, IL.ORCID 0000-0002-2772-3140
SOPHIA Study Group
MacroGenics (United States) · USVall d'Hebron Hospital Universitari · ESCentre Antoine Lacassagne · FRCentre François Baclesse · FRCentre Léon Bérard · FRChampalimaud Foundation · PTDartmouth–Hitchcock Medical Center · USFlorida Cancer Specialists & Research Institute · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEHospital Quirónsalud Barcelona · ESInstitut Curie · FRIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITItalian Oncology Group of Clinical Research · ITLakeridge Health · CAMaastricht University · NLMasaryk Memorial Cancer Institute · CZNorthwestern University · USRabin Medical Center · ILSaint Luke's Hospital · USSarah Cannon · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Breast NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesFemaleHumansTrastuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedErb-b2 Receptor Tyrosine KinasesmargetuximabTrastuzumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.